Search results
Obesity drug rivals aim to unseat Zepbound, Ozempic - Indianapolis Business Journal
Indianapolis Business Journal· 6 days agoInsatiable demand for weight-loss drugs has made the market so feverish that any positive mention of...
Amgen Soars as CEO Touts Experimental Obesity Drug Progress
Bloomberg· 6 days agoAmgen Inc.’s shares soared after its chief executive officer said he was “very encouraged” by early...
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Zacks via Yahoo Finance· 6 days agoAmgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged"...
Considering GLP-1s: A Guide to Deciding If It's Right for You
Healthline· 3 days agoModern medicine is continually advancing treatment options for many chronic health conditions. For...
Amgen Is 'Very Encouraged' With Its Obesity Drug. But Can It Take On Novo, Lilly Duopoly?
Investor's Business Daily· 5 days agoAmgen stock neared its record high Friday after the company said it's "very encouraged" with...
Amgen Soars as CEO Touts Experimental Obesity Drug Progress
Bloomberg via Yahoo Finance· 6 days ago(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very...
Amgen stock soars on positive obesity drug update, analysts raise PT
Investing.com· 6 days agoAmgen stock soars on positive obesity drug update, analysts raise PT
States consider whether to add coverage for some obesity medicines
NPR· 1 day agoMedicaid is required to cover almost all drugs, but Congress specifically excluded those for weight loss. Even so, 16 states now cover Wegovy. Others are considering it, but it could strain budgets.
Obesity, poor diet & physical inactivity driving early onset of cancers: Health expert
Investing.com· 5 days agoNew Delhi, May 4 (IANS) Obesity, poor diet, and physical inactivity are driving the onset of several...
Will Amgen Stock Continue To See Higher Levels Driven By Its Obesity Injection?
Forbes· 1 day agoFirstly, let us look at Amgen’s stock performance. AMGN stock has shown gains of 30% from levels of...